Clinical Trials Logo

Gout clinical trials

View clinical trials related to Gout.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06276556 Enrolling by invitation - Gout Clinical Trials

Extension Study of ABP-671 in Participants With Gout

Start date: April 22, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objectives of this study are to assess the safety, tolerability, and efficacy of ABP-671 in lowering serum uric acid (sUA) in participants with gout who roll over from Study ABP-671-301 after they complete the double-blind 28-week Treatment Period of Part 1 (Phase 2b) or Part 2 (Phase 3).

NCT ID: NCT06186219 Enrolling by invitation - Tophaceous Gout Clinical Trials

Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout

Start date: April 10, 2024
Phase: Phase 1
Study type: Interventional

This safety and feasibility, open-label study of up to 9 subjects will examine a group of subjects with poorly controlled tophaceous gout (intolerant to or ineffective oral urate lowering agents and loss of prior Pegloticase response) pre-treated with Rituximab to recapture response to Methotrexate-Pegloticase.

NCT ID: NCT03336203 Enrolling by invitation - Gout Clinical Trials

The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF)

IMPULsKF
Start date: October 30, 2017
Phase: Phase 4
Study type: Interventional

This trial aims to investigate the impact of two target levels uric acid-lowering therapy (ULT) caused by hyperuricemia (HU) on kidney function and CKD progression [1] measured by eGFR and albuminuria (A) [2]. The main current tasks include 1) estimation serum uric acid (SUA) level most potential preserving of kidney function 2) the new onset of gouts depending on SUA level, both in gouts' and CKD' objects 3) safety and side effects of target and ultralow SUA levels for evidence-based ULT optimal regime in CKD and non CKD with gout patients. 4) investigation of cardio vascular rick ratio depending on SUA level. The tasks also include 1. to determine U-curve or directly proportional relationship between SUA and eGFR-EPI in CKD 1-4 2. to evaluate the new onset of goat which depends on SUA level and renal function In this study the optimal ULT for kidney function based on target SUA level in 30 months' treatment with either allopurinol or febuxostat will be determined.